Sat, Dec 27, 2014, 8:04 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • 5-HT Obesity Medication Efficacy via POMC Activation is Maintained During Aging
    Burke LK et al
    Endocrinology. 2014 Oct (10):3732-8

    Abstract
    The phenomenon commonly described as the middle-age spread is the result of elevated adiposity accumulation throughout adulthood until late middle-age. It is a clinical imperative to gain a greater understanding of the underpinnings of age-dependent obesity and, in turn, how these mechanisms may impact the efficacy of obesity treatments. In particular, both obesity and aging are associated with rewiring of a principal brain pathway modulating energy homeostasis, promoting reduced activity of satiety pro-opiomelanocortin (POMC) neurons within the arcuate nucleus of the hypothalamus (ARC). We next investigated whether age-related diminished ARC POMC activity therefore impacts the potency of 5-HT obesity pharmacotherapies, lorcaserin, d-phenf..., and sibutramine and report that all compounds reduced food intake to a comparable extent in both chow-fed young lean (3-5 months old) and middle-aged obese (12-14 months old) male and female mice. We provide a mechanism through which 5-HT anorectic potency is maintained with age, via preserved 5-HT-POMC appetitive anatomical machinery. Specifically, the abundance and signaling of the primary 5-HT receptor influencing appetite via POMC activation, the 5-HT2CR, is not perturbed with age. These data reveal that although 5-HT obesity medications require ARC POMC neurons to achieve appetitive effects, the anorectic efficacy is maintained with aging, findings of clinical significance to the global aging obese population.
    ======
    Belviq maintains its anorectic potency and efficacy with aging.
    This is important weight-loss improves physical function, quality of life, and the medical complications associated with aging.
    Another study in a steady stream of positive articles...
    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • 43,000,000 X $3 A SHARE TO COVER = $129,000,000

    However, they can't get 43M shares at $3, so they will have to pay incrementally higher to cover all 43M. That would round out their potential losses closer to $1,000,000,000.

    ONE BILLION DOLLAR POTENTIAL LOSS is why there are bashers here 24/7 spreading lies.

    Sentiment: Strong Buy

  • **** EVERYONE should read it to fully understand why the Pumper's are here. ****
    Lesson 1: Remember, PUMPERS NEVER PUMP A GOOD STOCK. Check the boards for stocks with no potential They never have any Pumpers.
    Lesson 2: PUMPERS ALWAYS BRING UP OLD NEWS THAT YOU HAVE HEARD MANY TIMES. Pumpers will try to get you to think ARNA is a New startup with bits of bad news . The PUMPER will post this over and over again.
    Lesson 3: PUMPERS POST MANY TIMES A DAY. They try to wear you out. REMEMBER – LONGS… RESIST USING THE PUMPERS ALIAS!
    Lesson 4: PUMPERSS WILL LIE TO YOUR FACE. Never trust a PUMPER. The truth on startup companies is that they make mistakes. What new company hasn’t? The PUMPER will compare your issue to a another companies, financials – deals – management, etc., trying to lure you into making an Apples to Oranges comparison.PUMPERS WANT TO WHISPER IN YOUR EAR – PLANT A SEED OF HOPE. THEY PLAY ON YOUR NOT BEING SAVVY ENOUGH TO RESEARCH THE TRUTH ON YOUR OWN. This is how they achieve their greatest success. They have motives $$$$$$$$$$$$.
    Lesson 5: Pumpers know YOU CAN’T VERIFY THEIR STATEMENTS. That’s why they make the vague statements they do.
    Lesson 6: The Pumpers PLAY ON YOUR LACK OF KNOWLEDGE. They can lie about information and you won’t know the difference (unless you have done your own DD on the company and know the truth and facts).
    Lesson 7: Pumpers play on your patience. You have held a stock too long. You thought it was going be a big stock someday, but the losses keep coming PUMPERS WANT YOU TO HOLD AND HOLD. That’s when the PUMPER is best. The PUMPER posts hype as "news", so you will continue to hold. They DISTORT AND EXAGGERATE ANY INFORMATION TO GET YOU TO HOLD OR EVEN BUY MORE
    Lesson 8: BRING THE PRICE UP. That is the Pumpers job. The truth is not important. Lies are the norm. They are trying to comfort and soothe the newbies that are just investigating a stock

    Sentiment: Strong Sell

  • Belviq-only arm lost 3.8% of their body weight compared to baseline.

    Sentiment: Strong Sell

  • Lorcaserin Improves the NASH Clinical Score in the Majority of High-Risk Patients: a Retrospective Analysis of Three Phase 3 Studies
    We conducted a retrospective analysis to determine the ability of 52 weeks of lorcaserin 10 mg bid to improve NASH. The NASH clinical score predicts the presence of histologic NASH and was used as an indicator of NASH activity. Methods: Data were pooled from 3 clinical trials of similar design comparing lorcaserin and placebo in overweight or obese patients with or without type 2 diabetes. The modified intent-to-treat/last observation carried forward population was analyzed for patients with both baseline and end of treatment NASH clinical score data. The NASH clinical score was analyzed by comparing proportions of patients shifting from high or very high scores at baseline (NASH-pos) to low or intermediate scores (NASH-neg) at week 52. Results: Approximately 7% of control (182/2519) and lorcaserin-treated (190/2702) patients had a high-risk NASH clinical score, and both groups had an AST/ALT ratio of 0.9. LorcaLorcaserin-treated patients showed significant improvements vs placebo in ALT (% change from baseline to week 52, -2.4 vs 3.0), AST (0.1 vs 2.6) as well as significant weight loss (-5.8 vs -2.4), all P

  • it's nonsense. As if " trapped shorts" would pay monthly interest for more than 2 years. Just another pumper lie meant to make this stock seem desirable and valuable. It's not.

  • Adam,

    Your consistent, poorly-researched, moronic articles on Arena's Belviq anti-obesity drug, as compared to your "Goldilock's" promotion of Orexigen's black-boxed Contrave with 47 pages of negative side effects, is quite insulting to any informed investor with any intelligence. By trying to somehow juxtapose the idea that "Belviq is a chemical cousin of fenfluramine" in the same sentence with fenfluramine's ability to cause "damage to heart valves" is akin to claiming the metaphorical equivalence of guilt by association. Belviq is a novel drug which works on a totally different receptor from fenfluramine and has already been proven, via extensive clinical studies, to be the safest anti-obesity drug in the market, as compared to Vivus's Qsymia and Orexigen's Contrave. It is also currently and will be out-selling Qsymia and Contrave, as evidenced by Belviq's increasing acceptance by prescribers through its increasing weekly scripts.

    Again, you have succeeded in writing an article of inferior quality, devoid of any journalistic integrity, to promote your hidden agenda, which are obviously the qualities and values subscribed to by The Street. What a shame!

    Note: This rebuttal was posted on The Street.

    Sentiment: Strong Buy

  • One of the most important statements at the Biotech Conference was with regard to Renalapag used for the treatment of PAH made by Craig Audet:
    "We’ve completed the Phase 1 program for Renalapag (ph), what we saw was really nice half life around 25 hours which gives us the potential for once daily dosing"

    There are three anti-prostacyclins available today with two significant disadvantages: 1. Cost, 2. daily dosing route: implanted central venous catheter,
    intravenous or subcutaneous administration, and inhaled administration whic requires frequent doses.

    Renalapag has the potential for once a day dosing in tablet form. And it will cost considerably less both for the medication and the costs incurred by the
    administration method.

    There are three presently available- intravenous epoprostenol (Flolan), intravenous treprostinil (Remodulin), and inhaled iloprost ((ventavis). All of these have disadvantages of a short half life which means they have to be given continously over short periods of time.

    Problems with each:

    Epoprostenol (Flolan):
    Cost: $100,00 per year
    Must be delivered through a permanently implanted central venous catheter using a portable infusion pump which can result in thrombosis, pump malfunction, and interruption of infusion. These catheters can also contribute to mortality via these malfunctions of the pump.
    Most insures and both medicaid and medicare reimburse these costs

    Treprostinil (Remodulin)
    Cost: $120,000 to $160,000 per year
    Can be given intravenously or subcutaneously but subcutaneouns injection causes severe pain at the injection site
    Most insurers including medicaid and medicare pay for it

    Iloprost (Ventavis)
    Cost: $ 145,633 per year
    It is inhaled vs intravenous administration but the main disadvantage is the need for frequent inhalation - 6-9 times per day.

    IF CLINICAL TRIALS PROVE THE SAFETY AND EFFICACY OF THIS MEDICATION IT WILL HAVE A SIGNIFICANT ADVANTAGE IN BOTH DOSAGE ADMINISTRATION AND COST!!!!

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • IMS for week ended 10/3/2014

    Qsymia(VVUS) TRx/NRx 11206/7992 +.4%/+1.1%. w/w Belviq (ARNA) TRx/NRx 12388/9239 +4.7% +4.0% w/w

    I was unable to cute and paste and had to key this in.

  • Looks like we did just fine to me.

    Qsymia (VVUS) TRx/NRx 10923/7288 +21.3%/+19.0% w/w. Belviq
    (ARNA) TRx/NRx 11652/8066 +25.8%/+29.2% w/w. Contrave (OREX)
    TRx/NRx 5412/5283 +61.7%/+61.8% w/w

  • Patients with NAFLD (nonalcoholic fatty liver disease) and especially those with NASH frequently have one or more components of the metabolic syndrome:
    Obesity – in particular central obesity
    - In the BLOOM trial in year 1, lorcaserin use was associated with a significant decrease in waist circumference (baseline 109.6 cm) of 6.8 cm versus a decrease of 3.9 cm in the placebo arm and a decrease in BMI of 2.09 versus 0.78.
    - Treatment with belviq alone or with phent can decrease weight significantly
    Systemic hypertension
    - BLOOM trial: reduction in sys and dia BP
    Dyslipidemia
    - BLOOM trial: reduction in total cholesterol/LDL and cholesterol/triglyceride

    Insulin Resistance or overt diabetes
    - In the BLOOM trial, fasting blood glucose, insulin, and glycated hemoglobin (HBA1C) levels and insulin resistance also all decreased significantly more during year 1 in the lorcaserin group than in the placebo arm.
    In summary, BLOOM study demonstrated significantly reduced waist circumference (abdominal obesity), reduced fasting blood sugar, reduced A1C, reduced systolic anf diastolic blood pressure (hypertenssion), reduced total cholesterol/LDL cholesterol/triglycerides (dyslipidemia).

    The association was demonstrated in a study of 304 patients with NAFLD but without overt diabetes
    Liver biopsies were done in 163 patients and revealed NASH in 120 (74%)
    - Metabolic syndrome present in 53% who did not undergo biopsy
    - Metabolic syndrome in 67% with those with simple steatosis
    - Metabolic syndrome in 88% of those with NASH on biopsy

    Furthermore, metabolic syndrome was associated with increased risk of severe fibrosis, a risk factor for cirrhosis and hepatocellular carcinoma (HCC) – in one report of 137 patients with NASH and advanced fibrosis, the five year incidence of HCC was 8 percent.

    Multiple therapies have been investigated for treatment of NASH. Weight loss is THE ONLY THERAPY with reasonable evidence with beneficial and safe results.

    Daniel
    UCLA MD

    Sentiment: Strong Buy

  • johnrambo777@rocketmail.com by johnrambo777 Oct 15, 2014 10:10 AM Flag

    The only question you need to ask is.........will I be the last one to cover?

    Sentiment: Strong Buy

  • Every basher on this board has been here for several years- bashing ARNA retail has always been an inside job. Tick tock !!! !!! ! ......

  • "60 pound weight loss in 8 months without surgery"

    Sentiment: Strong Buy

  • This link is to the the infamous "Bas•. her's Handbook," a document which instructs hedge fund lackeys on directly how to damage stocks with misinformation campaigns.

    **** EVERYONE should read it to fully understand why the bashers are here. ****

    It is all part of their plan to bury this board in nonsense to interfere with real investors' ability to converse on the benefits of ARNA as a company.

    minamargroup.c*m/docs/bashers_handbook.pdf

    **MUST READ**

    Sentiment: Strong Buy

  • ... the potency of 5-HT obesity pharmacotherapies, lorcaserin, d-fenfluramine , and sibutramine ...you seem to have edited out the mention of fen( you reference it as d-phenf ) . So it seems Belviq acts like fen and sibutramine, both of which were of course recalled, in rat brains. Interesting. So, Belviq may also act like fen and sibutramine in human brains.

    Sentiment: Strong Sell

  • Shorts stockings soon stuffed with switches and lumps of coal. Tick tock !!!!! !! ! .........

  • They are trapped having shorted it below $2.

    There is no way they'd spend this much time, money and effort just to wring out a few more pennies on their short position. No one is that greedy and stupid. There are plenty of other stocks to go short on now and make faster money than here.

    Sentiment: Strong Buy

ARNA
3.42-0.15(-4.20%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST
Fluor Corporation
NYSEFri, Dec 26, 2014 4:03 PM EST